IRB Studies in Peptide Research: Why Clinics Should Participate

Institutional Review Board (IRB) oversight is the ethical and regulatory foundation of human subjects research. For medical practices working with peptides — whether GLP-1 compounds, RUO peptides, or emerging agents like retatrutide — IRB participation offers significant advantages that go beyond compliance.

An Institutional Review Board (IRB) is an independent committee that reviews, approves, and monitors research involving human subjects. IRBs are required by federal law (45 CFR Part 46, the "Common Rule") for research conducted or funded by federal agencies, and by FDA regulations (21 CFR Parts 50 and 56) for research involving FDA-regulated products.

IRBs evaluate research protocols to ensure:

• The risks to participants are minimized and reasonable in relation to anticipated benefits
• Participant selection is equitable
• Informed consent is properly obtained and documented
• Participant privacy and confidentiality are protected
• Vulnerable populations are appropriately protected

Institutional IRBs: Associated with universities, hospitals, or research institutions. Typically required for federally funded research.

Independent IRBs: Commercial IRBs that review research for organizations without their own IRB. These are the most relevant for private medical practices. Examples include WCG IRB, Advarra, and others.

Central IRBs: A single IRB that reviews research for multiple sites — common in multi-site clinical trials.

For private medical practices, an independent IRB is the typical pathway for establishing IRB oversight.

RUO (Research Use Only) compounds — including BPC-157, TB-500, CJC-1295/Ipamorelin, PT-141, sermorelin, and epithalon — cannot be administered to humans outside of a research context. IRB approval is the mechanism that creates a compliant research context.

Without IRB oversight, administering RUO compounds to patients is not compliant with FDA regulations. With IRB oversight, the same administration becomes part of a legitimate research protocol.

This is not a technicality — it is the difference between operating compliantly and operating outside the regulatory framework.

IRB-approved research protocols provide a pathway to access compounds that are not yet FDA-approved for therapeutic use — including retatrutide, novel peptide combinations, and other emerging agents.

For clinics that want to offer cutting-edge treatments, IRB participation is the compliant pathway.

IRB-approved research generates data. Data builds credibility. Clinics that participate in IRB research:

• Contribute to the evidence base for the compounds they use
• Build a track record of outcomes that differentiates them from competitors
• Position themselves as research-oriented practices that attract sophisticated patients

In the event of a regulatory inquiry, IRB approval is powerful documentation that your use of research compounds was conducted within an ethical and regulatory framework. It demonstrates that you took compliance seriously.

IRB-approved research can generate revenue through:

• Research participation fees (patients may pay to participate in research programs)
• Pharmaceutical company partnerships (companies pay sites to conduct research)
• Grant funding (for practices affiliated with academic institutions)

Work with an IRB consultant or the IRB itself to develop a research protocol. The protocol describes:

• The research question
• The compounds being studied
• The patient population
• The procedures (administration, monitoring, data collection)
• The informed consent process
• The risks and benefits

Submit the protocol to an independent IRB for review. The IRB will review the protocol and either approve it, request modifications, or reject it.

The IRB may require documentation of your facility's qualifications to conduct the research, including:

• Prescriber credentials
• Facility capabilities
• Staff training

Once approved, every research participant must provide written informed consent before participating. The consent document must be IRB-approved.

IRB approval is not a one-time event. You must:

• Report adverse events to the IRB
• Submit annual continuing review reports
• Report any protocol modifications for IRB approval

MedClinic Partners facilitates IRB enrollment for practices interested in participating in peptide and GLP-1 research. We work with independent IRBs and can help practices navigate the protocol development and submission process.

Contact us about IRB enrollment →

This content is for informational purposes only and does not constitute legal or regulatory advice. IRB requirements vary based on the type of research and the regulatory framework. Consult with qualified regulatory counsel.